Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy

Area of Science:

• Gastroenterology
• Cardiology
• Clinical Medicine

Background:

• The established safety of uninterrupted clopidogrel therapy during colonoscopy with polypectomy is not well-defined.
• Postpolypectomy bleeding (PPB) is a potential complication of endoscopic polyp removal.

Purpose of the Study:

• To evaluate the incidence and outcomes of PPB in patients taking clopidogrel.
• To identify independent risk factors for PPB in this patient population.

Main Methods:

• A retrospective, single-center study compared patients on clopidogrel (cases) with those not on the medication (controls).
• Demographics, clinical data, polyp characteristics, and polypectomy techniques were analyzed.
• Univariate and stepwise logistic regression analyses identified risk factors for PPB.

Main Results:

• Delayed PPB occurred more frequently in the clopidogrel group (3.5% vs. 1.0%, P = .02).
• Significant delayed bleeding requiring hospitalization or transfusion was also higher in the clopidogrel group (2.1% vs. 0.4%, P = .04).
• Concomitant use of clopidogrel with aspirin/NSAIDs and the number of polyps removed were significant risk factors for PPB.

Conclusions:

• While PPB rates are higher for patients on clopidogrel, particularly with concomitant NSAID use, the absolute risk is low and outcomes are generally favorable.
• Routine discontinuation of clopidogrel before colonoscopy and polypectomy is not indicated based on these findings.